Literature DB >> 438840

Glial fibrillary acidic protein (GFAP): purification from human fibrillary astrocytoma, development and validation of a radioimmunoassay for GFAP-like immunoactivity.

J W Palfreyman, D G Thomas, J G Ratcliffe, D I Graham.   

Abstract

The extraction and purification of glial fibrillary acidic protein (GFAP) from human fibrillary cerebellar astrocytoma is described. Using an immunoperoxidase method, antisera raised to the protein showed specific staining of astrocytes in normal spinal cord and in tumours of astrocytic origin. A double antibody radioimmunoassay for GFAP in tissue extract was developed, the detection limit of the assay being 360 pg. Extracts of tissues other than brain or spinal cord did not cross-react significantly in the assay, neither did purified preparations of myelin basic and S-100 proteins. Levels of GFAP in normal CNS tissue were higest in spinal cord (1370 microgram/g wet weight) but a level of 3050 microgram/g wet weight was detected in a fibrillary astrocytoma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438840     DOI: 10.1016/0022-510x(79)90144-8

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

1.  NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors.

Authors:  Leonard L Jones; Yu Yamaguchi; William B Stallcup; Mark H Tuszynski
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

2.  Spinal cord injury elicits expression of keratan sulfate proteoglycans by macrophages, reactive microglia, and oligodendrocyte progenitors.

Authors:  Leonard L Jones; Mark H Tuszynski
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

3.  Neuronal transgene expression in dominant-negative SNARE mice.

Authors:  Takumi Fujita; Michael J Chen; Baoman Li; Nathan A Smith; Weiguo Peng; Wei Sun; Michael J Toner; Benjamin T Kress; Linhui Wang; Abdellatif Benraiss; Takahiro Takano; Su Wang; Maiken Nedergaard
Journal:  J Neurosci       Date:  2014-12-10       Impact factor: 6.167

4.  Elevated GFAP induces astrocyte dysfunction in caudal brain regions: A potential mechanism for hindbrain involved symptoms in type II Alexander disease.

Authors:  Heather R Minkel; Tooba Z Anwer; Kara M Arps; Michael Brenner; Michelle L Olsen
Journal:  Glia       Date:  2015-07-17       Impact factor: 7.452

5.  Neuropeptides in neurological tumours.

Authors:  J M Allen; N R Hoyle; J C Yeats; M A Ghatei; D G Thomas; S R Bloom
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

6.  Anaplastic human gliomas grown in athymic mice. Morphology and glial fibrillary acidic protein expression.

Authors:  T R Jones; S H Bigner; S C Schold; L F Eng; D D Bigner
Journal:  Am J Pathol       Date:  1981-12       Impact factor: 4.307

7.  Clinically viable magnetic poly(lactide-co-glycolide) particles for MRI-based cell tracking.

Authors:  Dorit Granot; Michael K Nkansah; Margaret F Bennewitz; Kevin S Tang; Eleni A Markakis; Erik M Shapiro
Journal:  Magn Reson Med       Date:  2014-03       Impact factor: 4.668

8.  GFAP expression as an indicator of disease severity in mouse models of Alexander disease.

Authors:  Paige L Jany; Tracy L Hagemann; Albee Messing
Journal:  ASN Neuro       Date:  2013       Impact factor: 4.146

9.  Proteome-wide lysine acetylation in cortical astrocytes and alterations that occur during infection with brain parasite Toxoplasma gondii.

Authors:  Anne Bouchut; Aarti R Chawla; Victoria Jeffers; Andy Hudmon; William J Sullivan
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

10.  Interrelationship between differentiation and malignancy-associated properties in glioma.

Authors:  M C Frame; R I Freshney; P F Vaughan; D I Graham; R Shaw
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.